(1)
|
Pursuant
to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement
shall also cover an indeterminate number of shares of common stock, par value $0.001 per share (the “Common Stock”)
of Aspira Women’s Health Inc. (the “Company”) that may be issued and resold resulting from stock splits,
stock dividends or similar transactions. Represents shares of Common Stock that may be offered for resale (the “Resale
Shares”) by the selling stockholders described in this prospectus and are comprised of: (i) 5,915,850 shares of
Common Stock issued in connection with the conversion of the Convertible Notes, (ii) 11,848,177 shares of Common Stock underlying
the warrants underlying the Convertible Notes (as amended, the “Amended and Restated March 2025 Warrants”),
(iii) 6,550,000 shares of Common Stock issued pursuant to the securities purchase agreement dated September 16, 2025 (the “September
2025 Purchase Agreement”), and (iv) 4,912,500 shares of Common Stock underlying warrants issued in connection with the
September 2025 Purchase Agreement (the “September 2025 Warrants”). |